NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

眼科藥物-全球市場展望 (2020-2028)

Ophthalmic Drugs - Global Market Outlook (2020-2028)

出版商 Stratistics Market Research Consulting 商品編碼 1017788
出版日期 內容資訊 英文 150+ Pages
商品交期: 2-3個工作天內
價格
眼科藥物-全球市場展望 (2020-2028) Ophthalmic Drugs - Global Market Outlook (2020-2028)
出版日期: 2021年06月01日內容資訊: 英文 150+ Pages
簡介

2020年全球眼科藥物市場規模達到367億美元。

在預測期內,市場預計將以 8.5% 的複合年增長率增長,到 2028 年將達到 704.9 億美元。推動市場增長的關鍵因素包括與新藥開發相關的研發增加、對聯合療法開發的更多關注、技術進步、有利的報銷政策以及獲得醫療保健設施的機會增加。其中包括青光眼等眼科疾病的發病率增加、白內障和其他常見的眼部感染。然而,成熟藥物專利保護的到期阻礙了市場增長。

本報告調查了眼科藥物市場,以及市場概況,按類型、按技術、按藥物變異、按適應症、按分銷渠道、按給藥途徑、按劑型、按遞送類型、按治療類別,它提供最終用戶和區域趨勢,以及進入市場的公司概況。

目錄

第 1 章執行摘要

第 2 章前言

第 3 章市場趨勢分析

  • 簡介
  • 促進因素
  • 抑制因素
  • 市場機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • Covid-19 的影響

第 4 章波特五力分析

第 5 章全球眼科藥物市場:按類型

  • 簡介
  • 非處方藥
  • 處方藥

第 6 章全球眼科藥物市場:按技術

  • 簡介
  • 藥物輸送
  • 基因治療
  • 生物製藥
  • 小分子
  • 細胞療法

第 7 章全球眼科藥物市場:按藥物變化

  • 簡介
  • 仿製藥
  • 品牌藥

第 8 章全球眼科藥物市場:按適應症

  • 簡介
  • 青光眼
  • 乾眼症
  • 白內障
  • 視網膜病變
    • 糖尿病視網膜病變
    • 黃斑變性
  • 葡萄膜炎
  • 眼部感染/炎症/眼部過敏
  • 過敏性結膜炎
  • 年齡相關性黃斑變性 (AMD)
  • 糖尿病眼病
  • 其他
    • 睫毛少毛症
    • 視神經障礙

第 9 章全球眼科藥物市場:按分銷渠道

  • 簡介
  • 藥店
  • 醫院藥房
  • 網上藥店
  • 眼保健診所
  • 零售藥房/獨立藥房

第 10 章全球眼科藥物市場:按管理途徑

  • 簡介
  • 全身
  • 局部眼球
    • 球後
    • 結膜下
    • 在前房
    • 玻璃體內
  • 本地
  • 口服
  • 非口服

第 11 章全球眼科藥物市場:按劑型

  • 簡介
  • 固體眼科劑型
  • 液體眼科劑型
  • 多室給藥系統
  • 半固體眼科劑型

第 12 章全球眼科藥物市場:按交付類型

  • 簡介
  • 眼藥水
  • 膠囊和片劑
  • 眼膏
  • 凝膠
  • 滴眼液

第 13 章全球眼科藥物市場:按治療類別

  • 簡介
  • 消炎藥
    • 外用類固醇
    • 非甾體抗炎藥 (NSAID)
  • 抗生素
  • 抗過敏
  • 抗青光眼藥
    • 前列腺素類似物
    • 伴隨藥物
    • 阿爾法激動劑
    • Beta 阻斷劑
  • 抗血管生成
  • 抗感染藥
    • 抗真菌藥
    • 抗菌藥
    • 抗病毒藥物
  • 抗血管內皮生長因子 (VEGF) 劑
  • 視網膜藥
  • 其他治療類(環孢素)

第 14 章全球眼科藥物市場:按最終用戶

  • 簡介
  • 專科診所
  • 醫院
  • 藥房

第 15 章全球眼科藥物市場:按地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他

第 16 章主要發展

  • 合同、夥伴關係、合作、合資企業
  • 收購兼併
  • 推出新產品
  • 擴張
  • 其他重要策略

第 17 章公司簡介

  • Bayer AG
  • Abbott Healthcare
  • Merck & Co.
  • Pfizer, Inc.
  • Novartis AG
  • Valeant Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Allergan Plc
  • Santen Pharmaceutical Co. Ltd.
  • Genentech, Inc.
  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals Inc.
  • Aerie Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • Carl-Zeiss AG
  • Hoya Corporation
目錄
Product Code: SMRC20572

According to Stratistics MRC, the Global Ophthalmic Drugs market is accounted for $36.70 billion in 2020 and is expected to reach $70.49 billion by 2028 growing at a CAGR of 8.5% during the forecast period. Some of the key factors propelling the market growth include rising R&D pertaining to the development of novel drugs, increasing focus on developing combination therapies, rising advancements in technologies, favorable reimbursement policies, increasing accessibility for healthcare facilities, and increasing incidence of ophthalmic disorders such as glaucoma, cataract, and other common eye infections. However, loss of patent protection for popular drugs is restraining the market growth.

Ophthalmic drugs are used to treat eye infection and various types of eye conditions. These are used in the treatment of dry eye, age-related macular degeneration, diabetic retinopathy, and other eye disorders. Ophthalmic diseases, including age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy, retinal vein occlusion (RVO), and myopic choroidal neovascularization, are potential threats to an individual's sight. Ophthalmic drug forms have been one of the most important and widely developed areas of pharmaceutical technology over the few years.

By indication, the dry eye segment is anticipated to grow at the significant rate during the forecast period, increased dry eye cases among the peoples. Dry eye disease (DED) is a multifactorial disease of the tear film and ocular surface that results in ocular discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is a generally under-diagnosed clinical condition, as patients often attribute the experienced DED symptoms to ageing, and hence, it remains an under-researched condition in the low- and middle-income countries. In the last decade, only one drug was approved for the treatment of DED by the US Food and Drug Administration (FDA) (i.e., Restasis by Allergan Inc.). DED is a major public health problem, the burden of which is likely to increase due to the increasing proportion of the ageing population and the adoption of modern lifestyle.

On the basis of geography, the Asia Pacific is estimated to be the fastest-growing region in the market over the forecast period, due to increasing burden of ophthalmic disorders and rising consumer awareness. Glaucoma and tear substitute (for dry eye) drugs are the leading products in Asia-Pacific. India is likely to be among the top three pharmaceutical markets by incremental growth and the sixth-largest market, globally, in absolute size, according to the clinical and experimental vision and eye research, India, 2018. Moreover, increase in the number of middle-class households, advancement in medical infrastructure, and the increasing penetration of health insurance in the country are likely to play a significant role in influencing this growth.

Some of the key players in Ophthalmic Drugs Market include Bayer AG, Abbott Healthcare, Merck & Co., Pfizer, Inc., Novartis AG, Valeant Pharmaceuticals, Inc., Johnson & Johnson, Allergan Plc, Santen Pharmaceutical Co. Ltd., Genentech, Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Carl-Zeiss AG, and Hoya Corporation.

Types Covered:

  • Over-the-Counter Drugs
  • Prescription Drugs

Technologies Covered:

  • Drug Delivery
  • Gene Therapy
  • Biologics
  • Small Molecule
  • Cell Therapy

Drug Variations Covered:

  • Generic Drugs
  • Branded Drugs

Indications Covered:

  • Glaucoma
  • Dry Eye
  • Cataract
  • Retinal Disorders
  • Uveitis
  • Eye Infection/Inflammation/Eye Allergy
  • Allergic Conjunctivitis
  • Age-Related Macular Degeneration (AMD)
  • Diabetic Eye Disease
  • Other Indications

Distribution Channels Covered:

  • Drug Stores
  • Hospital Pharmacies
  • Online Pharmacies
  • Eye Health Clinics
  • Retail Pharmacies/Independent Pharmacies

Route of Administrations Covered:

  • Systemic
  • Local Ocular
  • Topical
  • Oral
  • Parenteral

Dosage Forms Covered:

  • Solid Ophthalmic Drug Forms
  • Liquid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Semisolid Ophthalmic Drug Forms

Delivery Types Covered:

  • Eye Solutions
  • Capsules & Tablets
  • Eye Ointment
  • Gels
  • Eye Drops

Therapeutic Classes Covered:

  • Anti-Inflammatory
  • Antibiotics
  • Anti-Allergy
  • Anti-Glaucoma Drugs
  • Anti-Angiogenic
  • Anti-Infective Drugs
  • Anti-Vascular Endothelial Growth Factor (VEGF) Agents
  • Retinal Drug
  • Other Therapeutic Classes (Cyclosporine)

End Users Covered:

  • Specialty Clinics
  • Hospitals
  • Pharmacy

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2019, 2020, 2021, 2025 and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis, etc.
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Ophthalmic Drugs Market, By Type

  • 5.1 Introduction
  • 5.2 Over-the-Counter Drugs
  • 5.3 Prescription Drugs

6 Global Ophthalmic Drugs Market, By Technology

  • 6.1 Introduction
  • 6.2 Drug Delivery
  • 6.3 Gene Therapy
  • 6.4 Biologics
  • 6.5 Small Molecule
  • 6.6 Cell Therapy

7 Global Ophthalmic Drugs Market, By Drug Variation

  • 7.1 Introduction
  • 7.2 Generic Drugs
  • 7.3 Branded Drugs

8 Global Ophthalmic Drugs Market, By Indication

  • 8.1 Introduction
  • 8.2 Glaucoma
  • 8.3 Dry Eye
  • 8.4 Cataract
  • 8.5 Retinal Disorders
    • 8.5.1 Diabetic Retinopathy
    • 8.5.2 Macular Degeneration
      • 8.5.2.1 Dry Age-Related Macular Degeneration
      • 8.5.2.2 Wet Age-Related Macular Degeneration
  • 8.6 Uveitis
  • 8.7 Eye Infection/Inflammation/Eye Allergy
  • 8.8 Allergic Conjunctivitis
  • 8.9 Age-Related Macular Degeneration (AMD)
  • 8.10 Diabetic Eye Disease
  • 8.11 Other Indications
    • 8.11.1 Eyelash Hypotrichosis
    • 8.11.2 Optic Neuropathy

9 Global Ophthalmic Drugs Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Drug Stores
  • 9.3 Hospital Pharmacies
  • 9.4 Online Pharmacies
  • 9.5 Eye Health Clinics
  • 9.6 Retail Pharmacies/Independent Pharmacies

10 Global Ophthalmic Drugs Market, By Route of Administration

  • 10.1 Introduction
  • 10.2 Systemic
  • 10.3 Local Ocular
    • 10.3.1 Retrobulbar
    • 10.3.2 Subconjunctival
    • 10.3.3 Intracameral
    • 10.3.4 Intravitreal
  • 10.4 Topical
  • 10.5 Oral
  • 10.6 Parenteral

11 Global Ophthalmic Drugs Market, By Dosage Form

  • 11.1 Introduction
  • 11.2 Solid Ophthalmic Drug Forms
  • 11.3 Liquid Ophthalmic Drug Forms
  • 11.4 Multicompartment Drug Delivery Systems
  • 11.5 Semisolid Ophthalmic Drug Forms

12 Global Ophthalmic Drugs Market, By Delivery Type

  • 12.1 Introduction
  • 12.2 Eye Solutions
  • 12.3 Capsules & Tablets
  • 12.4 Eye Ointment
  • 12.5 Gels
  • 12.6 Eye Drops

13 Global Ophthalmic Drugs Market, By Therapeutic Class

  • 13.1 Introduction
  • 13.2 Anti-Inflammatory
    • 13.2.1 Steroidal Drugs
    • 13.2.2 Non-Steroidal Anti-Inflammatory drugs (NSAIDs)
  • 13.3 Antibiotics
  • 13.4 Anti-Allergy
  • 13.5 Anti-Glaucoma Drugs
    • 13.5.1 Prostaglandin Analogs
    • 13.5.2 Combined Medication
    • 13.5.3 Alpha Agonist
    • 13.5.4 Beta-Blockers
  • 13.6 Anti-Angiogenic
  • 13.7 Anti-Infective Drugs
    • 13.7.1 Anti-Fungal Drugs
    • 13.7.2 Anti-Bacterial Drugs
    • 13.7.3 Anti-Viral Drugs
  • 13.8 Anti-Vascular Endothelial Growth Factor (VEGF) Agents
  • 13.9 Retinal Drug
  • 13.10 Other Therapeutic Classes (Cyclosporine)

14 Global Ophthalmic Drugs Market, By End User

  • 14.1 Introduction
  • 14.2 Specialty Clinics
  • 14.3 Hospitals
  • 14.4 Pharmacy

15 Global Ophthalmic Drugs Market, By Geography

  • 15.1 Introduction
  • 15.2 North America
    • 15.2.1 US
    • 15.2.2 Canada
    • 15.2.3 Mexico
  • 15.3 Europe
    • 15.3.1 Germany
    • 15.3.2 UK
    • 15.3.3 Italy
    • 15.3.4 France
    • 15.3.5 Spain
    • 15.3.6 Rest of Europe
  • 15.4 Asia Pacific
    • 15.4.1 Japan
    • 15.4.2 China
    • 15.4.3 India
    • 15.4.4 Australia
    • 15.4.5 New Zealand
    • 15.4.6 South Korea
    • 15.4.7 Rest of Asia Pacific
  • 15.5 South America
    • 15.5.1 Argentina
    • 15.5.2 Brazil
    • 15.5.3 Chile
    • 15.5.4 Rest of South America
  • 15.6 Middle East & Africa
    • 15.6.1 Saudi Arabia
    • 15.6.2 UAE
    • 15.6.3 Qatar
    • 15.6.4 South Africa
    • 15.6.5 Rest of Middle East & Africa

16 Key Developments

  • 16.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 16.2 Acquisitions & Mergers
  • 16.3 New Product Launch
  • 16.4 Expansions
  • 16.5 Other Key Strategies

17 Company Profiling

  • 17.1 Bayer AG
  • 17.2 Abbott Healthcare
  • 17.3 Merck & Co.
  • 17.4 Pfizer, Inc.
  • 17.5 Novartis AG
  • 17.6 Valeant Pharmaceuticals, Inc.
  • 17.7 Johnson & Johnson
  • 17.8 Allergan Plc
  • 17.9 Santen Pharmaceutical Co. Ltd.
  • 17.10 Genentech, Inc.
  • 17.11 F. Hoffmann-La Roche Ltd
  • 17.12 Regeneron Pharmaceuticals Inc.
  • 17.13 Aerie Pharmaceuticals Inc.
  • 17.14 Bausch Health Companies Inc.
  • 17.15 Carl-Zeiss AG
  • 17.16 Hoya Corporation

List of Tables

  • Table 1 Global Ophthalmic Drugs Market Outlook, By Region (2019-2028) ($MN)
  • Table 2 Global Ophthalmic Drugs Market Outlook, By Type (2019-2028) ($MN)
  • Table 3 Global Ophthalmic Drugs Market Outlook, By Over-the-Counter Drugs (2019-2028) ($MN)
  • Table 4 Global Ophthalmic Drugs Market Outlook, By Prescription Drugs (2019-2028) ($MN)
  • Table 5 Global Ophthalmic Drugs Market Outlook, By Technology (2019-2028) ($MN)
  • Table 6 Global Ophthalmic Drugs Market Outlook, By Drug Delivery (2019-2028) ($MN)
  • Table 7 Global Ophthalmic Drugs Market Outlook, By Gene Therapy (2019-2028) ($MN)
  • Table 8 Global Ophthalmic Drugs Market Outlook, By Biologics (2019-2028) ($MN)
  • Table 9 Global Ophthalmic Drugs Market Outlook, By Small Molecule (2019-2028) ($MN)
  • Table 10 Global Ophthalmic Drugs Market Outlook, By Cell Therapy (2019-2028) ($MN)
  • Table 11 Global Ophthalmic Drugs Market Outlook, By Drug Variation (2019-2028) ($MN)
  • Table 12 Global Ophthalmic Drugs Market Outlook, By Generic Drugs (2019-2028) ($MN)
  • Table 13 Global Ophthalmic Drugs Market Outlook, By Branded Drugs (2019-2028) ($MN)
  • Table 14 Global Ophthalmic Drugs Market Outlook, By Indication (2019-2028) ($MN)
  • Table 15 Global Ophthalmic Drugs Market Outlook, By Glaucoma (2019-2028) ($MN)
  • Table 16 Global Ophthalmic Drugs Market Outlook, By Dry Eye (2019-2028) ($MN)

Table17 Global Ophthalmic Drugs Market Outlook, By Cataract (2019-2028) ($MN)

  • Table 18 Global Ophthalmic Drugs Market Outlook, By Retinal Disorders (2019-2028) ($MN)
  • Table 19 Global Ophthalmic Drugs Market Outlook, By Diabetic Retinopathy (2019-2028) ($MN)
  • Table 20 Global Ophthalmic Drugs Market Outlook, By Macular Degeneration (2019-2028) ($MN)
  • Table 21 Global Ophthalmic Drugs Market Outlook, By Uveitis (2019-2028) ($MN)
  • Table 22 Global Ophthalmic Drugs Market Outlook, By Eye Infection/Inflammation/Eye Allergy (2019-2028) ($MN)
  • Table 23 Global Ophthalmic Drugs Market Outlook, By Allergic Conjunctivitis (2019-2028) ($MN)
  • Table 24 Global Ophthalmic Drugs Market Outlook, By Age-Related Macular Degeneration (AMD) (2019-2028) ($MN)
  • Table 25 Global Ophthalmic Drugs Market Outlook, By Diabetic Eye Disease (2019-2028) ($MN)
  • Table 26 Global Ophthalmic Drugs Market Outlook, By Other Indications (2019-2028) ($MN)
  • Table 27 Global Ophthalmic Drugs Market Outlook, By Eyelash Hypotrichosis (2019-2028) ($MN)
  • Table 28 Global Ophthalmic Drugs Market Outlook, By Optic Neuropathy (2019-2028) ($MN)
  • Table 29 Global Ophthalmic Drugs Market Outlook, By Distribution Channel (2019-2028) ($MN)
  • Table 30 Global Ophthalmic Drugs Market Outlook, By Drug Stores (2019-2028) ($MN)
  • Table 31 Global Ophthalmic Drugs Market Outlook, By Hospital Pharmacies (2019-2028) ($MN)
  • Table 32 Global Ophthalmic Drugs Market Outlook, By Online Pharmacies (2019-2028) ($MN)
  • Table 33 Global Ophthalmic Drugs Market Outlook, By Eye Health Clinics (2019-2028) ($MN)
  • Table 34 Global Ophthalmic Drugs Market Outlook, By Retail Pharmacies/Independent Pharmacies (2019-2028) ($MN)
  • Table 35 Global Ophthalmic Drugs Market Outlook, By Route of Administration (2019-2028) ($MN)
  • Table 36 Global Ophthalmic Drugs Market Outlook, By Systemic (2019-2028) ($MN)
  • Table 37 Global Ophthalmic Drugs Market Outlook, By Local Ocular (2019-2028) ($MN)
  • Table 38 Global Ophthalmic Drugs Market Outlook, By Retrobulbar (2019-2028) ($MN)
  • Table 39 Global Ophthalmic Drugs Market Outlook, By Subconjunctival (2019-2028) ($MN)
  • Table 40 Global Ophthalmic Drugs Market Outlook, By Intracameral (2019-2028) ($MN)
  • Table 41 Global Ophthalmic Drugs Market Outlook, By Intravitreal (2019-2028) ($MN)
  • Table 42 Global Ophthalmic Drugs Market Outlook, By Topical (2019-2028) ($MN)
  • Table 43 Global Ophthalmic Drugs Market Outlook, By Oral (2019-2028) ($MN)
  • Table 44 Global Ophthalmic Drugs Market Outlook, By Parenteral (2019-2028) ($MN)
  • Table 45 Global Ophthalmic Drugs Market Outlook, By Dosage Form (2019-2028) ($MN)
  • Table 46 Global Ophthalmic Drugs Market Outlook, By Solid Ophthalmic Drug Forms (2019-2028) ($MN)
  • Table 47 Global Ophthalmic Drugs Market Outlook, By Liquid Ophthalmic Drug Forms (2019-2028) ($MN)
  • Table 48 Global Ophthalmic Drugs Market Outlook, By Multicompartment Drug Delivery Systems (2019-2028) ($MN)
  • Table 49 Global Ophthalmic Drugs Market Outlook, By Semisolid Ophthalmic Drug Forms (2019-2028) ($MN)
  • Table 50 Global Ophthalmic Drugs Market Outlook, By Delivery Type (2019-2028) ($MN)
  • Table 51 Global Ophthalmic Drugs Market Outlook, By Eye Solutions (2019-2028) ($MN)
  • Table 52 Global Ophthalmic Drugs Market Outlook, By Capsules & Tablets (2019-2028) ($MN)
  • Table 53 Global Ophthalmic Drugs Market Outlook, By Eye Ointment (2019-2028) ($MN)
  • Table 54 Global Ophthalmic Drugs Market Outlook, By Gels (2019-2028) ($MN)
  • Table 55 Global Ophthalmic Drugs Market Outlook, By Eye Drops (2019-2028) ($MN)
  • Table 56 Global Ophthalmic Drugs Market Outlook, By Therapeutic Class (2019-2028) ($MN)
  • Table 57 Global Ophthalmic Drugs Market Outlook, By Anti-Inflammatory (2019-2028) ($MN)
  • Table 58 Global Ophthalmic Drugs Market Outlook, By Steroidal Drugs (2019-2028) ($MN)
  • Table 59 Global Ophthalmic Drugs Market Outlook, By Non-Steroidal Anti-Inflammatory drugs (NSAIDs) (2019-2028) ($MN)
  • Table 60 Global Ophthalmic Drugs Market Outlook, By Antibiotics (2019-2028) ($MN)
  • Table 61 Global Ophthalmic Drugs Market Outlook, By Anti-Allergy (2019-2028) ($MN)
  • Table 62 Global Ophthalmic Drugs Market Outlook, By Anti-Glaucoma Drugs (2019-2028) ($MN)
  • Table 63 Global Ophthalmic Drugs Market Outlook, By Prostaglandin Analogs (2019-2028) ($MN)
  • Table 64 Global Ophthalmic Drugs Market Outlook, By Combined Medication (2019-2028) ($MN)
  • Table 65 Global Ophthalmic Drugs Market Outlook, By Alpha Agonist (2019-2028) ($MN)
  • Table 66 Global Ophthalmic Drugs Market Outlook, By Beta-Blockers (2019-2028) ($MN)
  • Table 67 Global Ophthalmic Drugs Market Outlook, By Anti-Angiogenic (2019-2028) ($MN)
  • Table 68 Global Ophthalmic Drugs Market Outlook, By Anti-Infective Drugs (2019-2028) ($MN)
  • Table 69 Global Ophthalmic Drugs Market Outlook, By Anti-Fungal Drugs (2019-2028) ($MN)
  • Table 70 Global Ophthalmic Drugs Market Outlook, By Anti-Bacterial Drugs (2019-2028) ($MN)
  • Table 71 Global Ophthalmic Drugs Market Outlook, By Anti-Viral Drugs (2019-2028) ($MN)
  • Table 72 Global Ophthalmic Drugs Market Outlook, By Anti-Vascular Endothelial Growth Factor (VEGF) Agents (2019-2028) ($MN)
  • Table 73 Global Ophthalmic Drugs Market Outlook, By Retinal Drug (2019-2028) ($MN)
  • Table 74 Global Ophthalmic Drugs Market Outlook, By Other Therapeutic Classes (Cyclosporine) (2019-2028) ($MN)
  • Table 75 Global Ophthalmic Drugs Market Outlook, By End User (2019-2028) ($MN)
  • Table 76 Global Ophthalmic Drugs Market Outlook, By Specialty Clinics (2019-2028) ($MN)
  • Table 77 Global Ophthalmic Drugs Market Outlook, By Hospitals (2019-2028) ($MN)
  • Table 78 Global Ophthalmic Drugs Market Outlook, By Pharmacy (2019-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.